Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376877 · ClinicalTrials.gov registry record · Phase 2
Connectomic Targeted TMS Target for Refractory Anxiety
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT06376877 is a Phase 2 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 80 participants.
The verdict
NCT06376877, a Phase 2 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
We will perform a randomized sham-controlled trial of aiTBS to an anxiosomatic circuit in patients with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder). 80 participants with an anxiety-related disorder (defined below) will receive 50 active or sham TMS treatments over 5 days (following the SAINT protocol, which is FDA-cleared for MDD. The primary outcome will be the BAI, with a modified recall window to reflect the short treatment interval. Participants randomized to sham will be offered an open-label crossover extension.
Interventions
- PROCEDURE Transcranial magnetic stimulation
- PROCEDURE Sham transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376877
The ClinicalTrials.gov registry entry for NCT06376877 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial magnetic stimulation is the first listed.
NCT06376877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06376877 about?
NCT06376877 is a clinical study titled "Connectomic Targeted TMS Target for Refractory Anxiety". We will perform a randomized sham-controlled trial of aiTBS to an anxiosomatic circuit in patients with anxiety-related disorders (i.e., panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder). 80 participants with an ...
What is the current status of trial NCT06376877?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-08-01. Estimated completion is 2029-02-01.
What interventions are being tested in trial NCT06376877?
The interventions under investigation include: Transcranial magnetic stimulation (PROCEDURE), Sham transcranial magnetic stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT06376877?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.